methyl (trans-4-hydroxy-4-methylcyclohexyl)carbamate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl (trans-4-hydroxy-4-methylcyclohexyl)carbamate
• 英文别名: methyl N-(4-hydroxy-4-methylcyclohexyl)carbamate
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: RQYPJWVZDXAMBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-chloro-6-(4-ethylpiperazin-1-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-thione 、 methyl (trans-4-hydroxy-4-methylcyclohexyl)carbamate 在 三氟乙酸 作用下， 生成 methyl ((1r,4r)-4-((5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thio)-4-methylcyclohexyl)carbamate 、 methyl ((1s,4s)-4-((5-chloro-6-(4-ethylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)thio)-4-methylcyclohexyl)carbamate
  参考文献：
  名称：

  Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity

  摘要：

  A structure-activity relationship (SAR) study on the benzimidazole series of opioid receptor-like 1 (ORL1) antagonists related to 1 is described. Optimization of 1 by introduction of a hydrophilic substituent into the thioether part resulted in identification of potent ORL1 antagonists with high selectivity over binding affinity for hERG and other opioid receptors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.022
• 作为产物：
  描述：

  trans-4-amino-1-methylcyclohexanol 、 氯甲酸甲酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 methyl (trans-4-hydroxy-4-methylcyclohexyl)carbamate
  参考文献：
  名称：

  [EN] BROMODOMAIN INHIBITORS
  [FR] INHIBITEURS DE BROMODOMAINE

  摘要：

  本文提供了式（I）的化合物，其中R 1、Y、L 1、G 1、X 1、X 2、L 2、R 2、R 3和R 4具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗疾病和病况中是有用的，包括炎症性疾病、癌症和艾滋病。还提供了包含式（I）化合物的药物组合物。

  公开号：

  WO2018068283A1

文献信息

• Benzimidazole derivatives
  申请人：——

  公开号：US20040044056A1

  公开（公告）日：2004-03-04

  This invention relates to the compounds represented by a general formula [I]: 1 [in which A 1 and A 2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C 3 -C 20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及由一般式[I]表示的化合物：1[其中，A1和A2表示选择性氟代甲基或类似物；B表示卤素，氰基，低碳烷基或类似物；D表示选择性取代的杂环基团或类似物；G表示C3-C20脂肪族基团，例如脂环族基团]。这些化合物由于对痛觉受体具有高亲和力而抑制了痛觉肽活性，并且可用作镇痛剂，抗肥胖剂，脑功能改善剂，治疗阿尔茨海默病和痴呆症的药物，治疗精神分裂症和神经退行性疾病的药物，抗抑郁剂，治疗尿崩症，多尿症，低血压等的药物。
• BENZIMIDAZOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1342717A1

  公开（公告）日：2003-09-10

  This invention relates to the compounds represented by a general formula [I]:    [in which A1 and A2 represent optionally fluorine-substituted methine or the like; B represents halogen, cyano, lower alkyl or the like; D represents optionally substituted heterocyclic group or the like; and G represents C3-C20 aliphatic group such as alicyclic group]. These compounds inhibit nociceptin activities due to their high affinity to nociceptin receptor, and are useful as analgesic, antiobestic, corebral function improver, drugs for treatment of alzheimer's disease and dementia, remedies for schizophrenia and neurodegenerative diseases, antidepressant, remedies for diabetes insipidus, polyuria, hypotension and so on.

  本发明涉及通式[I]所代表的化合物： [其中 A1 和 A2 代表任选氟取代的甲基或类似物；B 代表卤素、氰基、低级烷基或类似物；D 代表任选取代的杂环基团或类似物；G 代表 C3-C20 脂肪族基团，例如脂环族基团]。这些化合物由于与痛觉素受体的高亲和力而抑制痛觉素的活性，可用作镇痛剂、抗镇静剂、改善大脑核心功能的药物、治疗老年痴呆症和痴呆症的药物、治疗精神分裂症和神经退行性疾病的药物、抗抑郁剂、治疗糖尿病、多尿、低血压等。
• US6969712B2
  申请人：——

  公开号：US6969712B2

  公开（公告）日：2005-11-29
• [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
  申请人：ABBVIE INC

  公开号：WO2018068283A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).

  本文提供了式（I）的化合物，其中R 1、Y、L 1、G 1、X 1、X 2、L 2、R 2、R 3和R 4具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗疾病和病况中是有用的，包括炎症性疾病、癌症和艾滋病。还提供了包含式（I）化合物的药物组合物。
• Optimization of benzimidazole series as opioid receptor-like 1 (ORL1) antagonists: SAR study directed toward improvement of selectivity over hERG activity
  作者：Kensuke Kobayashi、Tetsuya Kato、Izumi Yamamoto、Atsushi Shimizu、Sayaka Mizutani、Masanori Asai、Hiroshi Kawamoto、Satoru Ito、Takashi Yoshizumi、Mioko Hirayama、Satoshi Ozaki、Hisashi Ohta、Osamu Okamoto

  DOI：10.1016/j.bmcl.2009.04.022

  日期：2009.6

  A structure-activity relationship (SAR) study on the benzimidazole series of opioid receptor-like 1 (ORL1) antagonists related to 1 is described. Optimization of 1 by introduction of a hydrophilic substituent into the thioether part resulted in identification of potent ORL1 antagonists with high selectivity over binding affinity for hERG and other opioid receptors. (C) 2009 Elsevier Ltd. All rights reserved.